CD274 and neoplasm: Archival tumor molecular profiling of patients enrolled in the phase III first-line maintenance avelumab trial revealed that survival extension by avelumab was associated with PD-L1 expression by tumor cells, TMB, APOBEC mutation signatures, expression of innate and adaptive immune activity genes, and the number of alleles encoding high-affinity Fcꝩ receptors [23].